iFabric & Doctor's Choice(R) Sign Next-Generation Scrubs & Medical Apparel Agreement
iFabric Corp (OTCQX:IFABF) has announced that its subsidiary, Intelligent Fabric Technologies North America (IFTNA), has signed a significant licensing agreement with Mercury Athletics LLC to develop next-generation medical apparel under the Doctor's Choice® brand.
The collaboration will incorporate IFTNA's textile technologies, particularly PROTX2®, into healthcare scrubs and apparel. The partnership builds on Doctor's Choice's established reputation in diabetic and compression socks, expanding into the healthcare apparel sector. The new product line will be supported by IFTNA's peer-reviewed clinical trial published in the Journal of Hospital Infection in 2025.
iFabric Corp (OTCQX:IFABF) ha annunciato che la sua controllata Intelligent Fabric Technologies North America (IFTNA) ha siglato un importante accordo di licenza con Mercury Athletics LLC per lo sviluppo di abbigliamento medico di nuova generazione sotto il marchio Doctor's Choice®.
La collaborazione integrerà le tecnologie tessili di IFTNA, in particolare PROTX2®, nei camici e nell’abbigliamento sanitario. La partnership amplia la reputazione consolidata di Doctor's Choice nei collant e calze diabetiche e compressive, estendendola al settore dell’abbigliamento sanitario. La nuova linea di prodotti sarà supportata dal trial clinico peer-reviewed di IFTNA pubblicato nel Journal of Hospital Infection nel 2025.
iFabric Corp (OTCQX:IFABF) ha anunciado que su subsidiaria Intelligent Fabric Technologies North America (IFTNA) ha firmado un importante acuerdo de licencia con Mercury Athletics LLC para desarrollar indumentaria médica de próxima generación bajo la marca Doctor's Choice®.
La colaboración incorporará las tecnologías textiles de IFTNA, especialmente PROTX2®, en uniformes y prendas sanitarias. La asociación amplía la reconocida trayectoria de Doctor's Choice en calcetines diabéticos y de compresión, expandiéndose al sector de la vestimenta médica. La nueva línea de productos contará con el respaldo del ensayo clínico revisado por pares de IFTNA, publicado en Journal of Hospital Infection en 2025.
iFabric Corp (OTCQX:IFABF)가 자회사 Intelligent Fabric Technologies North America(IFTNA)가 Mercury Athletics LLC와 차세대 의료 의류를 Doctor's Choice® 브랜드로 개발하기 위한 중요한 라이선스 계약을 체결했다고 발표했습니다.
협력은 IFTNA의 섬유 기술, 특히 PROTX2®를 의료용 스크럽 및 의류에 통합할 것이며, 당뇨 및 압박 양말으로 이미 확립된 Doctor's Choice의 명성을 의료 의류 분야로 확장합니다. 새로운 제품 라인은 2025년 Journal of Hospital Infection에 게재된 IFTNA의 동료 심사 임상 시험으로 뒷받침될 것입니다.
iFabric Corp (OTCQX:IFABF) a annoncé que sa filiale Intelligent Fabric Technologies North America (IFTNA) a signé un accord de licence important avec Mercury Athletics LLC pour développer des vêtements médicaux de nouvelle génération sous la marque Doctor's Choice®.
La collaboration intégrera les technologies textiles d’IFTNA, en particulier PROTX2®, dans les blouses et vêtements de soins de santé. Le partenariat s’appuie sur la réputation déjà établie de Doctor's Choice dans les chaussettes diabétiques et de compression, et l’étend au secteur des vêtements médicaux. La nouvelle ligne de produits sera soutenue par l’essai clinique à révision par les pairs d’IFTNA publié dans le Journal of Hospital Infection en 2025.
iFabric Corp (OTCQX:IFABF) hat angekündigt, dass seine Tochtergesellschaft Intelligent Fabric Technologies North America (IFTNA) eine bedeutende Lizenzvereinbarung mit Mercury Athletics LLC unterzeichnet hat, um unter der Marke Doctor's Choice® die nächste Generation medizinischer Bekleidung zu entwickeln.
Die Kooperation wird die Textiltechnologien von IFTNA, insbesondere PROTX2®, in Gesundheits-Scrubs und -Bekleidung integrieren. Die Partnerschaft baut auf dem bereits etablierten Ruf von Doctor's Choice im Bereich diabetischer und Kompressionsstrümpfe auf und erweitert ihn auf den Sektor der Gesundheitsbekleidung. Die neue Produktlinie wird durch die peer-reviewed klinische Studie von IFTNA gestützt, die 2025 in der Journal of Hospital Infection veröffentlicht wurde.
iFabric Corp (OTCQX:IFABF) أعلنت أن الشركة التابعة لها Intelligent Fabric Technologies North America (IFTNA) قد وقّعت اتفاقية ترخيص مهمة مع Mercury Athletics LLC لتطوير ملابس طبية من الجيل التالي تحت علامة Doctor's Choice®.
ستدمج collaboration تقنيات الأقمشة لدى IFTNA، وخصوصاً PROTX2®، في سراويل العمل والملابس الصحية. الشراكة تُوسع سمعة Doctor's Choice في جوربDiabetes وCompressors إلى قطاع الملابس الصحية. ستُدعم خط الإنتاج الجديد بتجربة سريرية مُراجَعة من الأقران لـ IFTNA نُشرت في Journal of Hospital Infection في 2025.
iFabric Corp (OTCQX:IFABF) 公布其子公司 Intelligent Fabric Technologies North America (IFTNA) 已与 Mercury Athletics LLC 签署重要许可协议，计划以 Doctor's Choice® 品牌开发下一代医疗服装。
此次合作将把 IFTNA 的纺织技术，尤其是 PROTX2®，融入医疗手术服与医用服装。该伙伴关系在 Doctor's Choice 已在糖尿病及压力袜领域建立声誉的基础上，向医疗服装领域扩展。新产品线将得到 IFTNA 的同行评审型临床试验的支持，该试验于 2025 年在 Journal of Hospital Infection 发表。
- Partnership with established healthcare brand Doctor's Choice® expands market reach
- Integration of clinically-proven PROTX2® technology adds competitive advantage
- Expansion into new product category (scrubs) from existing sock business
- Validation through peer-reviewed clinical trial publication
- No specific timeline or sales projections provided
- Financial terms of the licensing agreement not disclosed
MARKHAM, ON / ACCESS Newswire / September 29, 2025 / iFabric Corp. ("iFabric" or the "Company") (TSX:IFA)(OTCQX:IFABF) today announced that its wholly owned subsidiary, Intelligent Fabric Technologies (North America) Inc. ("IFTNA"), has signed a license agreement with Mercury Athletics LLC, owner of the Doctor's Choice® brand, to design, manufacture, and market scrubs and medical apparel under the Doctor's Choice brand name. The program will incorporate multiple IFTNA textile technologies, led by PROTX2®, across relevant healthcare end-user categories and sales channels.
The Doctor's Choice brand is widely-recognized for diabetic and compression socks designed for foot health and all-day comfort, offering features such as non-binding tops and purpose-built graduated compression. This new agreement extends the brand into healthcare apparel while deepening an already strong product-technology relationship. Further information about Doctor's Choice is available at https://doctorschoice.com.
The collaboration will fully leverage iFabric's recently published peer-reviewed clinical trial, published in 2025 in the Journal of Hospital Infection and available online at: https://www.journalofhospitalinfection.com/article/S0195-6701(25)00222-1/fulltext
"Doctor's Choice is all about practical wellness-solutions that feel great and perform when it matters most. We're thrilled to bring that promise into scrubs, with IFTNA's technologies at the core," said Ty Schultz, President of Mercury Athletics LLC. "We couldn't ask for a better partner to help us deliver comfort and infection-prevention performance to consumers," concluded Mr. Schultz.
"This partnership unites a trusted healthcare brand with field-proven textile science," said Giancarlo Beevis," President & CEO of IFTNA. "With PROTX2® and our broader platform of advanced fabric finishes, these scrubs represent the next generation of infection-prevention tools-truly the doctors' choice… and nurses' and dentists', too," concluded Mr. Beevis.
Scope of Program, Timing, and Sales Channels
Under the license, IFTNA will design, manufacture, and market Doctor's Choice "scrubs" tops and pants across professional healthcare sales channels. Additional product details, timelines, and retail partners will be announced as programs finalize.
ABOUT PROTX2
ProTX2® is a powerful eco-friendly technology that provides antibacterial, antimicrobial, anti-mold, anti-mildew, and anti-odor protection. When treated, each textile fiber is fundamentally transformed through PROTX2®'s technology, providing proprietary unrivaled protection against pathogens associated with healthcare-associated infections as well as the toughest odors, for medical and performance textiles.
ABOUT iFABRIC CORP:
Headquartered in Markham, Ontario, iFabric, www.ifabriccorp.com, is listed on the TSX and, currently has 30.3 million shares issued and outstanding. Its two strategic divisions offer a variety of products and services through wholly-owned subsidiaries, namely, Intelligent Fabric Technologies (North America) Inc. ("IFTNA") and Coconut Grove Pads Inc. ("Coconut Grove").
IFTNA is focused on development and sale of high-performance sports apparel, medical protective apparel, consumer protective apparel, and proprietary treatments that provide "intelligent" properties to fabrics, foams, plastics, and numerous other surfaces, thereby improving the safety and well-being of the user. Such intelligent properties include antiviral and antibacterial characteristics, water-repellence and UV protection, among others.
Coconut Grove, operating as Coconut Grove Intimates, is a designer, manufacturer, distributor, licensor and licensee of ladies' intimate apparel products and accessories.
FORWARD LOOKING STATEMENTS
Forward-looking statements provide an opinion as to the effect of certain events and trends on the business. Certain statements contained in this news release constitute forward looking statements. The use of any words such as "anticipate", "continue", "plans", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the extent and impact of health pandemic outbreaks on our business; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; the actual results of the Company's future operations; competition; changes in legislation affecting the Company; the ability to obtain and maintain required permits and approvals, the timing and availability of external financing on acceptable terms; lack of qualified, skilled labour or loss of key individuals.
A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in the Company's annual information form dated March 28, 2025 and other filings with the Canadian securities regulators available under the Company's profile on SEDAR+ at www.sedarplus.ca. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.
Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made. Readers are cautioned not to place undue reliance on these statements as the Company's actual results, performance, or achievements may differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements if known or unknown risks, uncertainties or other factors affect the Company's business, or if the Company's estimates or assumptions prove inaccurate. Therefore, the Company cannot provide any assurance that forward-looking statements will materialize. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Any financial outlook or future oriented financial information in this news release, as defined by applicable securities legislation, has been approved by management of iFabric. Such financial outlook or future oriented financial information is provided for the purpose of providing information about management's reasonable expectations as to the anticipated results of its proposed business activities. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or any other reason except as required by applicable securities laws.
FOR FURTHER INFORMATION please contact:
Hylton Karon, President & CEO | Giancarlo Beevis, COO | Hilton Price, CFO |
Website: www.ifabriccorp.com
Neither the TSX Exchange nor its Regulations Services Provider (as that term is defined in the policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this press release.
SOURCE: iFabric Corp
View the original press release on ACCESS Newswire
FAQ
What is the new partnership between iFabric (IFABF) and Doctor's Choice®?
What technologies will be used in the Doctor's Choice® medical apparel?
When will the Doctor's Choice® scrubs be available for purchase?
What products does Doctor's Choice® currently offer?
What sales channels will be used for the new Doctor's Choice® scrubs?
